Clinical Trial Update: EASY: Extended Access to Sollpura Over Years [Phase 4]

View source ↗

Summary

Phase 4 extended-access study of Sollpura (pancrelipase) in Exocrine Pancreatic Insufficiency and Cystic Fibrosis completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Exocrine Pancreatic Insufficiency

Drugs mentioned

• Sollpura (pancrelipase)

Snippet

Sponsor: Anthera Pharmaceuticals | Conditions: Exocrine Pancreatic Insufficiency, Cystic Fibrosis | Phase 4 | Status: COMPLETED | Results posted: 2018-05-17